Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer

Published:2024-02 Issue: Volume:582 Page:216569
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Yang Yufan,Wang Jianyang,Wang Jingbo,Zhao Xiaotian^ORCID,Zhang Tao,Yang Yin,Pang Jiaohui,Ou Qiuxiang,Wu Linfang,Xu Xin,Xu Kunpeng,Zhao Jingjing,Bai Na,Yang Peng,Wang Sha,Wang Luhua,Bi Nan^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference54 articles.

1. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Aupérin;J. Clin. Oncol.,2010

2. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients;Taugner;Invest. N. Drugs,2021

3. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer;Taugner;Radiat. Oncol.,2020

4. Chemotherapy and surgery versus surgery alone in non‐small cell lung cancer;Burdett;Cochrane Database Syst. Rev.,2007

5. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non–small-cell lung cancer;Furuse;J. Clin. Oncol.,1999

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer;Future Oncology;2024-07-29

2. Variant Allele Frequency Analysis of Circulating Tumor DNA as a Promising Tool in Assessing the Effectiveness of Treatment in Non-Small Cell Lung Carcinoma Patients;Cancers;2024-02-14

3. Immunotherapy for lung cancer;Pathology - Research and Practice;2024-02